Date: 2016-01-18
Type of information: Nomination
Compound:
Company: Centauri Therapeutics (UK)
Therapeutic area: Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 18, 2016, Centauri Therapeutics, a biotechnology company focused on the treatment of infectious diseases, announced that it has appointed Dr Clive Dix as Chairman. Clive Dix has more than 25 years’ experience in the life sciences industry and is one of the UK’s leading pharma and biotech entrepreneurs. Clive was formerly co-founder and Chief Executive of Convergence Pharmaceuticals Ltd., acquired by Biogen Idec in 2015 in a deal worth up to $675 million. Previously, he was a founder and CEO of PowderMed Ltd, acquired by Pfizer in 2006; and Chairman of Auralis Ltd where he managed a successful US trade sale. Before that he was a main Board Director of PowderJect Pharmaceuticals plc until its acquisition by Chiron in 2003.
Financial terms:
Latest news:
